ELEDON PHARMACEUTICALS INC (ELDN) competitors & alternatives
Health Care · NASDAQ
ELEDON PHARMACEUTICALS INC (ELDN)'s top competitors and alternatives — its most similar public companies — include Vertex Pharmaceuticals (VRTX), NOVARTIS AG (NVS), REZOLUTE INC (RZLT), CULLINAN THERAPEUTICS INC (CGEM), MONOPAR THERAPEUTICS INC (MNPR), AVALYN PHARMA INC (AVLN), PRELUDE THERAPEUTICS INC (PRLD), MAPLIGHT THERAPEUTICS INC (MPLT), RAPPORT THERAPEUTICS INC (RAPP), KYVERNA THERAPEUTICS INC (KYTX), IMMUNOVANT INC (IMVT) and AbbVie (ABBV). These are ELEDON PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ELDN competitors & alternatives
-
Vertex PharmaceuticalsVRTXHealth Care
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and…
$473.09 (as of 2026-07-23) · market cap $119.3B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$156.14 (as of 2026-07-23) · market cap $228.8B
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.31 (as of 2026-07-23) · market cap $513M
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.28 (as of 2026-07-23) · market cap $1.1B
-
MONOPAR THERAPEUTICS INCMNPRHealth Care
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for…
$105.70 (as of 2026-07-23) · market cap $722M
-
AVALYN PHARMA INCAVLNHealth Care
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases.
$29.73 (as of 2026-07-23) · market cap $1.3B
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.93 (as of 2026-07-23) · market cap $311M
-
MAPLIGHT THERAPEUTICS INCMPLTHealth Care
MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, targeted treatments for central nervous…
$35.23 (as of 2026-07-23) · market cap $1.5B
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.38 (as of 2026-07-23) · market cap $2.0B
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.29 (as of 2026-07-23) · market cap $450M
-
IMMUNOVANT INCIMVTHealth Care
Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by…
$39.37 (as of 2026-07-23) · market cap $8.1B
-
AbbVieABBVHealth Care
Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases.
$256.92 (as of 2026-07-23) · market cap $447.5B
Not quite? Describe exactly what you want →
Peers are ELEDON PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ELEDON PHARMACEUTICALS INC (ELDN).
Last updated 2026-07-23.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.